Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6523
    +0.0005 (+0.08%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    106,293.38
    -3,057.45 (-2.80%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6043
    +0.0009 (+0.15%)
     
  • AUD/NZD

    1.0899
    -0.0003 (-0.03%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     

Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

Medtronic (MDT) closed at $108.55 in the latest trading session, marking a +0.93% move from the prior day. This change outpaced the S&P 500's 0.33% gain on the day. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.33%.

Heading into today, shares of the medical device company had lost 0.62% over the past month, lagging the Medical sector's gain of 3.22% and the S&P 500's gain of 2.66% in that time.

Investors will be hoping for strength from MDT as it approaches its next earnings release. In that report, analysts expect MDT to post earnings of $1.28 per share. This would mark year-over-year growth of 4.92%. Meanwhile, our latest consensus estimate is calling for revenue of $7.68 billion, up 2.62% from the prior-year quarter.

MDT's full-year Zacks Consensus Estimates are calling for earnings of $5.56 per share and revenue of $31.50 billion. These results would represent year-over-year changes of +6.51% and +3.09%, respectively.

ADVERTISEMENT

Any recent changes to analyst estimates for MDT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. MDT currently has a Zacks Rank of #3 (Hold).

Digging into valuation, MDT currently has a Forward P/E ratio of 19.34. This valuation marks a discount compared to its industry's average Forward P/E of 26.22.

It is also worth noting that MDT currently has a PEG ratio of 2.64. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 2.62 based on yesterday's closing prices.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 36% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research